Dr. John Z. Zhu is the founder, president, chief investment officer, and managing member of
Mayewell Capital, LLC. Prior to forming Mayewell Capital, LLC, Dr. Zhu worked for GlaxoSmithKline, a global
pharmaceutical company in Philadelphia, PA in drug development for 16 years.
There, Dr. Zhu was involved in drug development processes in multiple therapeutic areas including antimicrobials,
osteoporosis, nonalcoholic steatohepatitis and metabolic diseases, and was responsible for designing and conducting
clinical trials, data analyses, and report compilations. In addition, he was also responsible for new drug application
package submissions and regulatory correspondence with agencies in the US, Europe and globally, constantly evaluating
the efficacy and safety data of drugs in market or in development.
Dr. Zhu has invested in healthcare, life sciences and other industries through numerous market cycles for 10 years,
employing value-investing principles laid out by Benjamin Graham and Warren Buffett. Through these experiences,
Dr. Zhu is able to combine his science and business acumen as a pioneer in applying value-investing principles and
business-owner mindset in evaluating opportunities in the biotechnology sector, and has successfully obtained
superior returns in the past 6 years. Particularly, Dr. Zhu considers margin of safety in this sector as both buying
at a sensible price for the business and low risk in efficacy and safety attributes of the pipeline drugs in
development by the business.